CelLBxHealth Reports FY2025 Results: Strategic Repositioning and Cost Reductions Pave Way for Growth

That is encouraging because it says the issue was more about low sales volume and weak commercial conversion than poor pricing or a broken product mix. In plain English, the business did not sell enough, but what it did sell still carried decent margin.

Why the operating loss got worse – and why investors should look under the bonnet

The operating loss widened to £19.2 million from £15.1 million, and the loss after tax rose to £19.5 million from £14.2 million. On the face of it, that is ugly.

But there is some context. The 2025 loss included £1.2 million of cash restructuring costs and £6.5 million of non-cash costs. Non-cash costs are accounting charges that hit profit but do not immediately drain cash, and these included impairment charges – effectively a write-down in asset values when management decides prior investments are not worth what they were once carried at.

Even so, this is not a result to sugar-coat. A business with £1.4 million of revenue losing £19.5 million after tax is still in a very early and risky phase, no matter how sensible the restructuring might be.

Cost cutting at CelLBxHealth is dramatic – 60% headcount reduction and one-site model

This is the part of the update management clearly wants investors to focus on. The company says it has completed a major restructuring that should reduce annualised operating cash costs to about £6.7 million, with annual cost savings of around £6.6 million.

That has been achieved through a 60% reduction in headcount, consolidation into a single operating location, and renegotiated supplier contracts. Further efficiencies were made in Q1 2026, cutting employee numbers from 44 to 39.

My view is that this is painful but necessary. CelLBxHealth was simply too expensive for the level of revenue it was generating, so management had little choice but to shrink the business to preserve cash and buy time.

Cash runway, fundraise and the going concern warning – the bit investors really cannot ignore

CelLBxHealth ended 2025 with £7.3 million of cash, down from £10.4 million a year earlier. By 31 March 2026, that had fallen further to £4.3 million.

The company says it has cash runway into Q2 2027. Cash runway just means how long current cash is expected to last before more money is needed.

Here is the important catch: the audited accounts include an unmodified audit report with a material uncertainty related to going concern. That sounds technical, but it is a serious flag. It means the auditors signed off the accounts, but they are highlighting significant doubt over the company’s ability to keep operating in the normal course unless forecast revenues arrive and further funding is secured beyond H1 2027.

So yes, the December 2025 fundraise of £8.2 million gross was vital. But no, it has not removed funding risk altogether. Existing shareholders should also remember that the company issued 816,760,990 new ordinary shares in that fundraising, so survival came with substantial dilution.

Partnerships with AstraZeneca, Roche, QIAGEN and others are the real commercial test

The strategic pivot is simple enough: stop trying to build every downstream tool in-house and instead get the Parsortix platform working alongside established diagnostic and analysis systems already used by labs and pharma groups.

That is why the collaborations matter. The company highlighted work with QIAGEN, Roche Diagnostics, Illumina and Myriad, and after the year end it added a Master Services Agreement with AstraZeneca, a collaboration with AdventHealth, and research work with The Royal Marsden NHS Foundation Trust.

For a company like this, those names do two things. First, they provide third-party validation that the technology is worth serious attention. Second, they create possible routes to future revenue without CelLBxHealth having to build a massive commercial machine on its own.

The caution is obvious though: collaborations are not the same thing as material sales. They are promising, but investors still need to see conversion into repeat revenue.

CelLBxHealth outlook for 2026 – at least 50% revenue growth, but from a very low base

Management expects FY2026 revenue of at least £2.1 million, based on contracted revenue and near-term opportunities. That would represent growth of at least 50% versus FY2025.

On one level, that is a decent rebound. On another, it still only takes revenue back to a level that remains small versus the company’s cost base and historic expectations.

The company also said its qualified commercial pipeline has grown by 22% over the last quarter. That is encouraging, but pipeline is not cash. The key job now is execution – closing deals, validating workflows, and proving that partnership-led growth can turn scientific relevance into commercial traction.

My verdict on CelLBxHealth’s preliminary results – better structured, still high risk

I think this RNS is mixed, but more credible than many small-cap life sciences updates because it does not pretend 2025 was good. It plainly was not. Revenue disappointed badly, losses were heavy, and the going concern warning tells you the financing risk is real.

The positive case is that the company now looks leaner, more realistic and better aligned with the market. It has strengthened leadership, cut costs hard, and built links with serious industry players.

For retail investors, the investment case now hinges on one thing: can CelLBxHealth turn these partnerships and validation programmes into sustainable revenues before it needs more capital? If the answer becomes yes, this reset year could prove worthwhile. If not, the funding question will come back into view very quickly.